2394-25-4

Basic information

• Product Name: 17-Deoxy Cortienic Acid
• Synonyms: 17-Deoxy Cortienic Acid
• CAS NO: 2394-25-4
• Molecular Formula: C₂₀H₂₈O₄
• Molecular Weight: 332.43392
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals, Steroids
• Mol File: 2394-25-4.mol
• Article Data: 4

Chemical Properties

• Melting Point: 253-255 °C
• Boiling Point: 527.0±50.0 °C(Predicted)
• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Acetonitrile (Slightly, Heated), Chloroform (Slightly, Heated), DMSO (Slightly),
• PKA: 4.71±0.70(Predicted)
• CAS DataBase Reference: 17-Deoxy Cortienic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 17-Deoxy Cortienic Acid(2394-25-4)
• EPA Substance Registry System: 17-Deoxy Cortienic Acid(2394-25-4)

Safety Data

• Hazardous Substances Data: 2394-25-4(Hazardous Substances Data)

Usage

Uses

17-Deoxy Cortienic Acid was used in the synthetic preparation of macrolactonolides, a class of potential antiinflammatory drugs.

Upstream product

• 10486-85-8 (8S,9S,10R,11S,13S,14S,17S)-methyl 11-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8, 9,10,11,12,13, 14, 15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-carboxylate 
• 50-23-7 HYDROCORTISONE 
• 64-17-5 ethanol 
• 7664-93-9 sulfuric acid 
• 50-22-6 Corticosterone 
• 110247-37-5 11β-hydroxy-3-oxo-5β-androstane-17β-carboxylic acid 

Relevant articles and documents

17-KETOSTEROIDS VIA A BASE INDUCED CLEAVAGE OF C-17-DIHYDROXY ACETONE SIDE CHAINS

A new, base-catalyzed cleavage of C21-steroids to give 17-ketosteroids is described.This reaction is specific for those steroids containing the C-17-dihydroxy acetone side chain.In the presence of oxygen, these same reaction conditions readily degrade corticosterone to the 17β-carboxylic acid.

Raw synthesis and mitochondrial function postischemic mitochondria diseases related to the lack or for use in new compd. 11β-hydroxysteroid

The present invention provides novel compounds of 112-hydroxy steroids and compositions and their application as pharmaceuticals for preventing or reversing injury to mitochondria, for treating or preventing diseases relating to mitochondrial dysfunction or depletion, and for inducing regeneration or restructuring of mitochondria as a means of treating diseases relating to abnormalities in mitochondrial structure and function in a human or animal subject. Also disclosed herein are methods for diagnosing injury to mitochondria and for diagnosing the success or failure of therapeutics designed to treat, prevent, or reverse injury to or depletion of mitochondria.

Macrolactonolides: A novel class of anti-inflammatory compounds

A new concept in design of safe glucocorticoid therapy was introduced by conjugating potent glucocorticoid steroids with macrolides (macrolactonolides). These compounds were synthesized from various steroid 17β-carboxylic acids and 9a-N-(3-aminoalkyl) derivatives of 9-deokso-9a-aza-9a-homoeritromicin A and 3-descladinosyl-9-deokso-9a-aza-9a-homoeritromicin A using stable alkyl chain. Combining property of macrolides to preferentially accumulate in immune cells, especially in phagocyte cells, with anti-inflammatory activity of classic steroids, we designed molecules which showed good anti-inflammatory activity in ovalbumin (OVA) induced asthma in rats. The synthesis, in vitro and in vivo anti-inflammatory activity of this novel class of compounds are described.